Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
- 1 April 2021
- journal article
- editorial
- Published by Elsevier BV in Gastroenterology
- Vol. 160 (5), 1452-1460.e21
- https://doi.org/10.1053/j.gastro.2020.10.065
Abstract
No abstract availableFunding Information
- Samsung
- Takeda Pharmaceutical Company
- Ferring Pharmaceuticals
- Gilead Foundation
- Janssen Pharmaceuticals
This publication has 92 references indexed in Scilit:
- Validation of the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and healthGut, 2011
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospitalEuropean Journal of Gastroenterology & Hepatology, 2011
- Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's diseaseGut, 2011
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortGastroenterology, 2010
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scandinavian Journal of Gastroenterology, 2009
- Impact of Inflammatory Bowel Disease on Health-Related Quality of LifeDigestive Diseases, 1999
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Quality of Life in Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1992